Facebook tracking pixel
L51.9
ICD-10-CM
Erythema Multiforme

Learn about Erythema Multiforme (EM), including EM Major and EM Minor, diagnosis, clinical documentation, and medical coding. Find information on Erythema Multiforme symptoms, causes, treatment, and ICD-10 codes for accurate healthcare records and billing. This resource provides essential guidance for clinicians and healthcare professionals on properly documenting and coding EM in medical settings.

Also known as

EM
EM Major
EM Minor

Diagnosis Snapshot

Key Facts
  • Definition : An acute, self-limiting, inflammatory skin reaction, often triggered by infections or medications.
  • Clinical Signs : Target-like lesions, blisters, and/or mucosal involvement. May have fever or malaise.
  • Common Settings : Outpatient, Dermatology, Infectious Disease or Allergy clinics. Hospitalization in severe cases (EM major).

Related ICD-10 Code Ranges

Complete code families applicable to AAPC L51.9 Coding
L51-L54

Erythema multiforme

Inflammatory skin disorder with target lesions.

L00-L99

Diseases of the skin and subcutaneous tissue

Includes various skin conditions like infections, inflammation, and ulcers.

R21

Rash and other nonspecific skin eruption

Covers unspecified skin rashes when a more precise diagnosis isn't available.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the Erythema Multiforme (EM) drug-induced?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Acute, immune-mediated skin reaction.
Severe mucocutaneous reaction with epidermal detachment.
Mild form of Erythema Multiforme.

Documentation Best Practices

Documentation Checklist
  • Document target-like lesions or macules/papules.
  • Describe lesion distribution (acral, truncal, oral).
  • Note mucosal involvement (oral, genital, ocular).
  • Record presence/absence of systemic symptoms (fever, malaise).
  • Specify EM subtype (minor, major, SJS/TEN overlap).

Coding and Audit Risks

Common Risks
  • EM Severity Miscoding

    Incorrectly coding EM Major as EM Minor or vice versa, impacting reimbursement and quality metrics. CDI crucial for specificity.

  • Causality Documentation

    Lack of documentation linking EM to underlying cause (e.g., HSV, medication) leads to coding and billing errors. Crucial for medical necessity.

  • Stevens-Johnson Syndrome Overlap

    Misdiagnosing overlapping SJS/TEN as EM, leading to incorrect, lower severity coding and affecting quality reporting and outcomes analysis.

Mitigation Tips

Best Practices
  • Discontinue causative drug (ICD-10-CM L51.1, CDI: Document reaction onset)
  • Topical corticosteroids for localized lesions (SNOMED CT 70618009, RxNorm: 649752)
  • Oral antihistamines for itching relief (ICD-10-CM L51.0, optimize coding)
  • Cool compresses, bland emollients soothe skin (patient education, compliance)
  • Severe EM: Systemic corticosteroids (SNOMED CT 390008001, justify use in documentation)

Clinical Decision Support

Checklist
  • 1. Confirm target-like lesions or macules/papules. ICD-10: L51.1 Document morphology.
  • 2. Assess mucosal involvement (EM major) or absence (EM minor). ICD-10: L51.0, L51.2
  • 3. Rule out herpes simplex virus (HSV) or Mycoplasma pneumoniae infection. Document triggers.
  • 4. Evaluate for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) overlap. Careful DDX.

Reimbursement and Quality Metrics

Impact Summary
  • Erythema Multiforme (EM) reimbursement hinges on accurate ICD-10-CM coding (L51.x) for maximized claim acceptance and minimized denials.
  • Coding quality directly impacts EM metrics reporting, influencing hospital quality scores and potential value-based payments.
  • Precise EM documentation (type, severity, cause) is crucial for appropriate DRG assignment and accurate reimbursement.
  • Miscoded EM (e.g., with SJS/TEN) can lead to claim rejections, impacting revenue cycle and hospital financial performance.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: How can I differentiate between erythema multiforme minor and erythema multiforme major (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis overlap) in my clinical practice?

A: Differentiating erythema multiforme (EM) minor from EM major, which represents the milder end of the Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) spectrum, requires careful assessment of mucosal involvement and skin detachment. EM minor typically presents with target lesions and limited or no mucosal involvement. While oral lesions may occur, they are usually mild. In contrast, EM major involves more widespread and severe mucosal erosions affecting at least two mucosal sites (e.g., oral, ocular, genital). Additionally, EM major exhibits epidermal detachment affecting less than 10% of the body surface area (BSA). Skin biopsies can be helpful in ambiguous cases. Explore how histopathological findings can further aid in distinguishing these conditions. Consider implementing a standardized skin assessment protocol in your practice to accurately document the extent of skin and mucosal involvement for appropriate diagnosis and management.

Q: What are the most common drug triggers for erythema multiforme, and how should I approach medication management in a patient with suspected drug-induced EM?

A: Several medications are commonly implicated in erythema multiforme (EM) reactions. These include sulfonamides, anticonvulsants (e.g., phenytoin, carbamazepine, lamotrigine), nonsteroidal anti-inflammatory drugs (NSAIDs), allopurinol, and certain antibiotics (e.g., penicillins, cephalosporins). If drug-induced EM is suspected, the offending medication should be immediately discontinued. A thorough medication history is crucial. Learn more about the Naranjo Algorithm and other causality assessment tools to help determine the likelihood of a drug being the causative agent. If the patient requires alternative medications for their underlying condition, careful consideration should be given to potential cross-reactivity within drug classes. Consider implementing a phased reintroduction of medications under close observation when necessary.

Quick Tips

Practical Coding Tips
  • Code EM to L51.1
  • Document lesion morphology
  • Specify major/minor if known
  • Consider Stevens-Johnson/TEN differential
  • Rule out drug-induced EM

Documentation Templates

Patient presents with symptoms consistent with Erythema Multiforme (EM), likely EM minor.  Onset of the rash was reported as [duration] ago, characterized by [description of lesions - e.g.,  well-defined, erythematous target lesions, macules, papules, vesicles, bullae] distributed on [location of lesions - e.g., extremities, palms, soles, oral mucosa].  Patient denies fever, malaise, or systemic symptoms.  Lesions are [description of discomfort - e.g., pruritic, painful, burning].  No mucosal involvement noted.  Patient reports [possible triggering factor - e.g., recent herpes simplex virus infection, medication exposure,  Mycoplasma pneumoniae infection].  Differential diagnoses considered include Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug eruption, and urticaria.  Based on clinical presentation and history, the diagnosis of Erythema Multiforme minor is favored.  Treatment plan includes [treatment - e.g., symptomatic management with antihistamines, topical corticosteroids, discontinuation of suspected causative medication].  Patient education provided regarding  EM prognosis, recurrence prevention, and potential complications.  Follow-up scheduled in [duration] to monitor resolution and assess for any progression of symptoms.  ICD-10-CM code L51.1 (Erythema multiforme) is assigned.